DAIICHI SANKYO, INC. for DAIICHI SANKYO INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 19, 2016 | $100,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Oct 27, 2016 | $90,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding the Affordable Care Act (ACA) Discussions regarding prescription drug abuse Discussions regarding Drug sales information reporting (DSIR) Discussions regarding Food Drug & Cosmetic Act Discussions regarding 340B Drug Program
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Medicare/Medicaid MMM
Discussions regarding Medicare
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.